Hualan Biological Vaccine Inc. Stock

Equities

301207

CNE1000058J9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-04-25 EDT 5-day change 1st Jan Change
21.28 CNY -8.87% Intraday chart for Hualan Biological Vaccine Inc. -6.13% -23.45%

Financials

Sales 2024 * 2.93B 405M 553M Sales 2025 * 3.56B 491M 672M Capitalization 12.77B 1.76B 2.41B
Net income 2024 * 1.04B 143M 195M Net income 2025 * 1.28B 177M 242M EV / Sales 2024 * 4.36 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.59 x
P/E ratio 2024 *
12.3 x
P/E ratio 2025 *
9.96 x
Employees 770
Yield 2024 *
3.34%
Yield 2025 *
3.95%
Free-Float 13.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day-8.87%
1 week-6.13%
Current month-10.89%
1 month-9.52%
3 months-11.66%
6 months-23.73%
Current year-23.45%
More quotes
1 week
20.73
Extreme 20.73
23.54
1 month
20.73
Extreme 20.73
24.57
Current year
19.16
Extreme 19.16
27.93
1 year
19.16
Extreme 19.16
36.50
3 years
19.16
Extreme 19.16
53.19
5 years
19.16
Extreme 19.16
53.19
10 years
19.16
Extreme 19.16
53.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 35 22-03-28
Director of Finance/CFO 43 20-05-31
Chief Tech/Sci/R&D Officer 49 17-03-31
Members of the board TitleAgeSince
Chairman 75 13-03-31
Director/Board Member 52 13-03-31
Director/Board Member 56 13-05-31
More insiders
Date Price Change Volume
24-04-26 21.28 -8.87% 9,825,559
24-04-25 23.35 +1.17% 2,336,800
24-04-24 23.08 -1.03% 1,949,108
24-04-23 23.32 +1.00% 2,306,634
24-04-22 23.09 +1.85% 2,163,052

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Hualan Biological Vaccine Inc, formerly Hualan Biological Bacterin Inc, is a China-based company principally engaged in the research, development, production and sales of human vaccines. The Company's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The Company's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The Company's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21.28 CNY
Average target price
33.2 CNY
Spread / Average Target
+56.02%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 301207 Stock